## Thomas A Murray

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8507184/publications.pdf

Version: 2024-02-01

24 papers 1,125 citations

840776 11 h-index 713466 21 g-index

27 all docs

27 docs citations

times ranked

27

1367 citing authors

#	Article	IF	CITATIONS
1	An Alternative Metric for Evaluating the Potential Patient Benefit of Response-Adaptive Randomization Procedures. Biometrics, 2023, 79, 1433-1445.	1.4	1
2	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). Clinical Trials, 2022, 19, 52-61.	1.6	16
3	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. Annals of Internal Medicine, 2022, 175, 234-243.	3.9	56
4	Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms. Open Forum Infectious Diseases, 2022, 9, ofac066.	0.9	17
5	Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury. JAMA Network Open, 2022, 5, e222735.	5.9	42
6	Batch Bayesian optimization design for optimizing a neurostimulator. Biometrics, 2021, 77, 661-674.	1.4	0
7	Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. The Lancet Healthy Longevity, 2021, 2, e34-e41.	4.6	160
8	Optimization of Spinal Cord Stimulation Using Bayesian Preference Learning and Its Validation. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2021, 29, 1987-1997.	4.9	18
9	Mobile Health Intervention to Close the Guidelines-To-Practice Gap in Hypertension Treatment: Protocol for the mGlide Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e25424.	1.0	1
10	Logistic retainment interval dose exploration design for Phase I clinical trials of cytotoxic agents. Pharmaceutical Statistics, 2021, 20, 850-863.	1.3	1
11	Alternative models and randomization techniques for Bayesian response-adaptive randomization with binary outcomes. Clinical Trials, 2021, 18, 417-426.	1.6	2
12	Morbidity and Mortality Trends of Pancreatitis: An Observational Study. Surgical Infections, 2021, 22, 1021-1030.	1.4	8
13	A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19. EClinicalMedicine, 2021, 37, 100957.	7.1	56
14	Body mass index prediction rule for mid-upper arm circumference. Blood Pressure Monitoring, 2021, Publish Ahead of Print, .	0.8	0
15	Bayesian variable selection in hierarchical difference-in-differences models. Statistical Methods in Medical Research, 2021, , 096228022110510.	1.5	1
16	Bridging randomized controlled trials and single-arm trials using commensurate priors in arm-based network meta-analysis. Annals of Applied Statistics, 2021, 15, .	1.1	4
17	Rationale and methods of the Advanced R2Eperfusion STrategies for Refractory Cardiac Arrest (ARREST) trial. American Heart Journal, 2020, 229, 29-39.	2.7	24
18	Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. Lancet, The, 2020, 396, 1807-1816.	13.7	519

#	Article	IF	CITATION
19	Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2. Critical Care, 2020, 24, 182.	5.8	8
20	Comparative review of novel modelâ€essisted designs for phase I clinical trials. Statistics in Medicine, 2018, 37, 2208-2222.	1.6	57
21	A Utility-Based Design for Randomized Comparative Trials with Ordinal Outcomes and Prognostic Subgroups. Biometrics, 2018, 74, 1095-1103.	1.4	12
22	Utilityâ€based designs for randomized comparative trials with categorical outcomes. Statistics in Medicine, 2016, 35, 4285-4305.	1.6	19
23	Combining nonexchangeable functional or survival data sources in oncology using generalized mixture commensurate priors. Annals of Applied Statistics, 2015, 9, 1549-1570.	1.1	11
24	Semiparametric Bayesian commensurate survival model for postâ€market medical device surveillance with nonâ€exchangeable historical data. Biometrics, 2014, 70, 185-191.	1.4	23